- Home
- GH
as 11-10-2025 3:32pm EST
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 4.9B | IPO Year: | 2018 |
| Target Price: | $74.32 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $28.45 - $101.57 | Next Earning Date: | 10-29-2025 |
| Revenue: | $902,569,000 | Revenue Growth: | 30.38% |
| Revenue Growth (this year): | 33.95% | Revenue Growth (next year): | 25.77% |
Stock Insider Trading Activity of Guardant Health Inc. (GH)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Saia John G. | GH | Chief Legal Officer | Nov 7 '25 | Sell | $96.25 | 8,996 | $865,865.00 | 43,172 | |
| Hidalgo Medina Manuel | GH | Director | Nov 7 '25 | Sell | $95.20 | 1,500 | $142,780.15 | 1,315 | |
| Tariq Musa | GH | Director | Oct 17 '25 | Sell | $66.95 | 116 | $7,766.20 | 7,725 | |
| POTTER MYRTLE S | GH | Director | Oct 17 '25 | Sell | $66.95 | 26 | $1,740.70 | 18,324 | |
| Tariq Musa | GH | Director | Sep 17 '25 | Sell | $55.63 | 116 | $6,453.08 | 7,725 | |
| POTTER MYRTLE S | GH | Director | Sep 17 '25 | Sell | $55.63 | 26 | $1,446.38 | 18,324 | |
| Hidalgo Medina Manuel | GH | Director | Sep 12 '25 | Sell | $54.16 | 2,165 | $117,250.77 | 1,315 | |
| Eltoukhy Helmy | GH | Co-Chief Executive Officer | Sep 9 '25 | Sell | $59.69 | 300,000 | $17,835,995.20 | 2,123,499 | |
| Joyce Meghan V. | GH | Director | Sep 2 '25 | Sell | $65.84 | 100 | $6,584.00 | 11,183 | |
| Kalia Kumud | GH | Chief Information Officer | Aug 21 '25 | Sell | $61.76 | 2,000 | $123,510.00 | 18,500 |
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
How FDA Approval of Guardant360 CDx as Companion Diagnostic Could Impact Guardant Health (GH) Investors
Simply Wall St.
a month ago
Is Quest Diagnostics' (DGX) Shield Partnership Transforming Its Role in Preventive Health Innovation?
GlobeNewswire
a month ago
GCC Liquid Biopsy Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Bio-Rad, Thermo Fisher Scientific, Johnson & Johnson, Guardant Health, QIAGEN, Sysmex
Insider Monkey
a month ago
Guardant Health, Inc. (GH) Unveils Shield V2, Boosts Early Cancer Detection Accuracy
StockStory
2 months ago
Testing & Diagnostics Services Q2 Earnings: Guardant Health (NASDAQ:GH) is the Best in the Biz
StockStory
2 months ago
Q2 Earnings Recap: Guardant Health (NASDAQ:GH) Tops Testing & Diagnostics Services Stocks
Business Wire
2 months ago
Alex M. Azar II Joins Guardant Health Board of Directors
Barrons.com
2 months ago
More Blood Tests for Cancer Hit the Market
Compare GH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.